Ready-to-use Cell-free Secretomes for Wound Healing

Secretomes are protein molecules that are secreted or released from cells and are actively involved in control and regulation of biological processes in the body like wound healing, skin formation etc. Scientists at NCCS have created a novel skin repair product using these secretomes. Their invention includes novel composition of secretomes for wound healing, which are derived from electro-spun nano-fiber scaffolds seeded with bone marrow and peripheral blood derived 
cells (BMPCs); and a method of manufacturing these secretomes into ready-to-use salves. These salves can be directly applied onto the skin repair site for accelerating the wound healing process.

Figure 1: Migration of Endothelial Progenitor Cells (EPCs) to the wound site is key in wound healing process. S1 and S2 are two compositions of secretomes and both promote EPC proliferation and migration as compared to VN control.

This cell-free wound-healing product can be manufactured using secretomes derived from both autologous as well as allogeneic cells without any risk of rejection. It can be made into cryopreserved salves, which are reusable after thawing and have long shelf life of couple of months to half a year when stored at 4°C to -20°C respectively.

Figure 2: In-vitro study showing potency of secretomes composition (S2) in enhancing EPC proliferation in EPCs derived from diabetic as well as non-diabetic human subjects.

This novel product facilitates wound healing even in diseased conditions like Diabetes, where the skin repair function is impaired and provides a scar-free healing. It can be used for healing wounds caused by burns, cuts, scratches, surgical procedures, non-healing diabetic ulcers etc. Further, this product has been observed to establish normal glucose levels in diabetic conditions, promote hair growth in injured area, aid in growth of fat tissue, and stimulate bone growth along with wound-healing in in-vivo animal models.

Figure 3: S1 actively promotes bone growth (osteogenesis) as compared to controls, in-vitro.

Technology Readiness: TRL B2 (In-vitro + In-vivo efficacy/ results demonstrated)

Technology Status: Patent filed in India.

Technology Availability: Know-how available for transfer/ co-development with partners.